| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1093 | 2019 |
| GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas RG Majzner, S Ramakrishna, KW Yeom, S Patel, H Chinnasamy, ... Nature 603 (7903), 934-941, 2022 | 414 | 2022 |
| Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma AH Lee, L Sun, AY Mochizuki, JG Reynoso, J Orpilla, F Chow, JC Kienzler, ... Nature communications 12 (1), 6938, 2021 | 106 | 2021 |
| Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma E Ladomersky, L Zhai, KL Lauing, A Bell, J Xu, M Kocherginsky, B Zhang, ... Clinical Cancer Research 26 (19), 5232-5245, 2020 | 68 | 2020 |
| Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation TB Davidson, A Lee, M Hsu, S Sedighim, J Orpilla, J Treger, M Mastall, ... Clinical Cancer Research 25 (6), 1913-1922, 2019 | 64 | 2019 |
| Evidence for innate and adaptive immune responses in a cohort of intractable pediatric epilepsy surgery patients GC Owens, AJ Garcia, AY Mochizuki, JW Chang, SD Reyes, N Salamon, ... Frontiers in Immunology 10, 121, 2019 | 20 | 2019 |
| Precision medicine in pediatric neurooncology: a review AY Mochizuki, IM Frost, MB Mastrodimos, AS Plant, AC Wang, TB Moore, ... ACS chemical neuroscience 9 (1), 11-28, 2018 | 14 | 2018 |
| GABAergic neuron-to-glioma synapses in diffuse midline gliomas T Barron, B Yalçın, A Mochizuki, E Cantor, K Shamardani, D Tlais, ... bioRxiv, 2022.11. 08.515720, 2022 | 8 | 2022 |
| A pilot study of low-dose craniospinal irradiation in patients with newly diagnosed average-risk medulloblastoma JE Minturn, AY Mochizuki, S Partap, JB Belasco, BJ Lange, Y Li, ... Frontiers in Oncology 11, 744739, 2021 | 7 | 2021 |
| Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas RG Majzner, S Ramakrishna, A Mochizuki, S Patel, H Chinnasamy, ... Cancer Research 81 (13_Supplement), CT031-CT031, 2021 | 6 | 2021 |
| Epct-14. GD2 Car T-Cells Mediate Clinical Activity and Manageable Toxicity in Children and Young Adults with H3k27m-Mutated Dipg and Spinal Cord DMG R Majzner, S Ramakrishna, A Mochizuki, S Patel, H Chinnasamy, K Yeom, ... Neuro-Oncology 23 (Supplement_1), i49-i50, 2021 | 5 | 2021 |
| Omic-11. Single cell RNA sequencing from the csf of subjects with h3k27m+ dipg/dmg treated with gd2 car t-cellular therapy A Mochizuki, S Ramakrishna, Z Good, S Patel, H Chinnasamy, K Yeom, ... Neuro-oncology 23 (Supplement_1), i39-i39, 2021 | 3 | 2021 |
| ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL R Prins, A Mochizuki, J Orpilla, A Lee, T Davidson, S Gaffey, C Sanders, ... Neuro-oncology 20 (suppl_6), vi3-vi3, 2018 | 3 | 2018 |
| GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. RG Majzner, S Ramakrishna, A Mochizuki, S Patel, H Chinnasamy, ... CANCER RESEARCH 81 (13), 2021 | 2 | 2021 |
| Atim-39. Improved survival noted in glioblastoma patients treated with adjuvant tlr-3 agonist in setting of autologous lysate-pulsed dc vaccination J Antonios, R Everson, H Soto, S Khattab, J Bethel, M Sun, A Mochizuki, ... Neuro-oncology 20 (Suppl 6), vi10, 2018 | 2 | 2018 |
| ATIM-25. neoadjuvant PD-1 antibody blockade is associated with focal upregulation of PD-L1 and CD8 T cell infiltrate in recurrent glioblastoma J Orpilla, A Mochizuki, J Reynoso, N Akkad, A Lee, T Davidson, L Liau, ... Neuro-oncology 20 (Suppl 6), vi6, 2018 | 2 | 2018 |
| Is Tel Hashomer camptodactyly a distinct clinical entity? A Mochizuki, J Hyland, T Brown, TP Slavin American Journal of Medical Genetics Part A 167 (1), 255-258, 2015 | 2 | 2015 |
| TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL … A Mochizuki, A Lee, J Orpilla, J Kienzler, M Galvez, F Chow, T Davidson, ... Neuro-oncology 21 (Supplement_6), vi248-vi248, 2019 | 1 | 2019 |
| ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA F Chow, A Mochizuki, A Lee, M Galvez, J Orpilla, R Everson, L Liau, ... Neuro-oncology 21 (Suppl 6), vi4, 2019 | 1 | 2019 |
| IMMU-22. single-cell characterization of intratumoral and systemic immune populations in pediatric and adult brain tumors reveals differences in subpopulation composition … A Mochizuki, A Lee, A Garcia, R Prins, A Wang, T Davidson Neuro-oncology 21 (Suppl 2), ii97, 2019 | 1 | 2019 |
